Novus Biologicals Announces New PINK1 Antibody Made Using SDIX Genomic Antibodies
Summary
SDIX GAT uses sophisticated bioinformatics and immunization strategies to produce high-quality antibodies that specifically bind to targeted regions of the protein in its naturally folded form.The ability of an antibody to recognize a protein’s naturally folded state enables its utility in high-value applications like sandwich immunoassay, ChIP, and flow cytometry.For over 20 years, SDIX has been a leading immuno-solutions Company, developing results-oriented and innovative antibody-based solutions that enable customers to meet high performance research, diagnostic and commercialization objectives.In the food safety market, SDIX continues to expand its footprint as an international supplier of rapid pathogen test technologies that enable more accurate and cost effective results.Such risks and uncertainties include, without limitation, changes in demand for products, the application of our technologies to various uses, delays in product development, delays in market acceptance of new products, retention of customers and employees, adequate supply of raw materials, inability to obtain or delays in obtaining fourth party or required government approvals, the ability to meet increased market demand, competition, protection of intellectual property, non-infringement of intellectual property, seasonality, and other factors more fully described in SDIXs public filings with the U.S. Securities and Exchange Commission.### Contact Information Novus Biologicals Amy Chamberlain-Torres 303-730-1950 www.NovusBio.com Click here to view the list of recent Press Releases from Novus Biologicals Promote Your Business Press Release Pricing Email this page to a friend